Follow
Paul Toren
Paul Toren
Verified email at crchudequebec.ulaval.ca
Title
Cited by
Cited by
Year
Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of …
L Klotz, C O'Callaghan, K Ding, P Toren, D Dearnaley, CS Higano, ...
Journal of Clinical Oncology 33 (10), 1151, 2015
2002015
Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities
P Toren, A Zoubeidi
International journal of oncology 45 (5), 1793-1801, 2014
1742014
Combination AZD5363 with enzalutamide significantly delays enzalutamide-resistant prostate cancer in preclinical models
P Toren, S Kim, T Cordonnier, C Crafter, BR Davies, L Fazli, ME Gleave, ...
European urology 67 (6), 986-990, 2015
1182015
Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer
PJ Toren, S Kim, S Pham, A Mangalji, H Adomat, EST Guns, A Zoubeidi, ...
Molecular cancer therapeutics 14 (1), 59-69, 2015
982015
Small incidentally discovered testicular masses in infertile men—is active surveillance the new standard of care?
PJ Toren, M Roberts, I Lecker, ED Grober, K Jarvi, KC Lo
The Journal of urology 183 (4), 1373-1377, 2010
722010
Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients
FH Joncas, F Lucien, M Rouleau, F Morin, HS Leong, F Pouliot, Y Fradet, ...
The Prostate 79 (15), 1767-1776, 2019
622019
Results of a national population-based study of outcomes of surgery for renal tumors associated with inferior vena cava thrombus
P Toren, R Abouassaly, N Timilshina, G Kulkarni, S Alibhai, A Finelli
Urology 82 (3), 572-578, 2013
592013
Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study
P Toren, D Margel, G Kulkarni, A Finelli, A Zlotta, N Fleshner
bmj 346, 2013
582013
Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?
L Klotz, P Toren
Current oncology 19 (s1), 13-21, 2012
572012
Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: A randomized study
D Santa Mina, MK Connor, SMH Alibhai, P Toren, C Guglietti, AG Matthew, ...
Canadian Urological Association Journal 7 (11-12), E692, 2013
512013
Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer
PJ Toren, ME Gleave
Asian journal of andrology 15 (3), 342, 2013
512013
Periprostatic adipose tissue and prostate cancer progression: new insights into the tumor microenvironment
P Toren, V Venkateswaran
Clinical genitourinary cancer 12 (1), 21-26, 2014
452014
Combined AKT and MEK pathway blockade in pre-clinical models of enzalutamide-resistant prostate cancer
P Toren, S Kim, F Johnson, A Zoubeidi
PLoS One 11 (4), e0152861, 2016
362016
Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer
A Zardan, KM Nip, D Thaper, P Toren, S Vahid, E Beraldi, L Fazli, ...
Oncogenesis 3 (8), e115-e115, 2014
362014
Sex steroids in the tumor microenvironment and prostate cancer progression
C Boibessot, P Toren
Endocrine-Related Cancer 25 (3), R179-R196, 2018
312018
Comparison of epidural and intravenous patient controlled analgesia in patients undergoing radical cystectomy.
P Toren, S Ladak, C Ma, S McCluskey, N Fleshner
The Canadian journal of urology 16 (4), 4716-4720, 2009
312009
PEG10 is associated with treatment-induced neuroendocrine prostate cancer
S Kim, D Thaper, S Bidnur, P Toren, S Akamatsu, JL Bishop, C Colins, ...
Journal of Molecular Endocrinology 63 (1), 39-49, 2019
282019
Catastrophic sepsis and hemorrhage following transrectal ultrasound guided prostate biopsies
P Toren, R Razik, J Trachtenberg
Canadian Urological Association Journal 4 (1), E12, 2010
252010
Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer
J Pelletier, SJ Cyr, AS Julien, Y Fradet, L Lacombe, P Toren
Urologic Oncology: Seminars and Original Investigations 36 (8), 363. e7-363. e11, 2018
242018
Neutrophil-to-lymphocyte ratio as a predictive marker of response to abiraterone acetate: a retrospective analysis of the COU302 study
T Loubersac, M Nguile-Makao, F Pouliot, V Fradet, P Toren
European Urology Oncology 3 (3), 298-305, 2020
222020
The system can't perform the operation now. Try again later.
Articles 1–20